CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · IEX Real-Time Price · USD
2.140
+0.020 (0.94%)
At close: May 1, 2024, 4:00 PM
2.150
+0.010 (0.47%)
After-hours: May 1, 2024, 4:05 PM EDT
CytoMed Therapeutics Employees
CytoMed Therapeutics had 27 employees on March 27, 2023. The number of employees increased by 3 or 12.50% since the number was last reported on November 18, 2022.
Employees
27
Change
3
Growth
12.50%
Revenue / Employee
n/a
Profits / Employee
-$115,962
Market Cap
24.67M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 27, 2023 | 27 | 3 | 12.50% |
Nov 18, 2022 | 24 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
GDTC News
- 6 weeks ago - CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Accesswire
- 6 weeks ago - CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - GlobeNewsWire
- 2 months ago - CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewsWire
- 3 months ago - Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - GlobeNewsWire
- 5 months ago - CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PRNewsWire
- 5 months ago - CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PRNewsWire
- 6 months ago - CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - PRNewsWire
- 6 months ago - CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology - Accesswire